We aimed to evaluate the benefits of the glycoprotein ( GP ) IIb/IIIa antagonist , eptifibatide , after patients with acute coronary syndromes ( ACS ) were admitted to hospitals that approach revascularization for ACS through early transfer to tertiary referral centers .
